CLL RESONATE-2: Five-year follow-up
RESONATE-2 trial of ibtrutinib in CLL
RESONATE 2 (Disc 1) - Mixed by The Freak
RESONATE 2 (Disc 2) Mixed by The Freak
7-year follow-up of RESONATE-2 trial for CLL/SLL
RESONATE, RESONATE-2 and HELIOS: three major clinical trials in CLL research
RESONATE-2: ibrutinib and chlorambucil for frontline CLL
RESONATE-2 follow up: ibrutinib and chlorambucil 5 years on
The RESONATE-2 Study
Late-Breaking Abstract: RESONATE 2 Finds First-Line Ibrutinib Superior to Chlorambucil in CLL/SLL
Upfront Ibrutinib: RESONATE-2 Trial
Dr. Brown on Lessons Learned From RESONATE-2 Trial for CLL
Resonate 2
Dr. Jennifer Brown on RESONATE 2 Trial in CLL
Overview of RESONATE-2 clinical trial of ibrutinib in CLL
RESONATE-2 Trial: Safety and Efficacy Updates
Clinical Impact of the RESONATE-2 Trial in CLL
Overview of the RESONATE-2 clinical trial of ibrutinib as front-line therapy
RESONATE-2: Five-year follow up of CLL patients receiving ibrutinib as first-line treatment
Outcomes from the RESONATE 2 and HELIOS Trials—Clinical Impact
